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Previously, we synthesized a series of -diketo acid metal complexes as novel HIV-1 integrase (IN) inhibitors
(J. Med. Chem. 2006, 46, 4248-4260). Herein, a further extension of this study is reported. First, detailed
docking studies were performed in order to investigate the mode of binding in the active site of the free
ligands and of their metal complexes. Second, a series of potentiometric measurements were conducted for
two diketo acids chosen as model ligands, with Mn2+ and Ca2+, in order to outline a speciation model.
Third, we designed and synthesized a new set of complexes with different stoichiometries and tested them
in an in vitro assay specific for IN. Finally, we obtained the first X-ray structure of a metal complex with
HIV-1 IN inhibition activity. Analysis of these results supports the hypothesis that the diketo acids could
act as complexes and form complexes with the metal ions on the active site of the enzyme.
Introduction
HIV-1 integrase (INa) is an essential enzyme for viral
replication1-4 and a validated target for the development of
drugs against AIDS.5-7 It functions as a multimer8 to catalyze
the insertion of viral cDNA into the host genome to form a
stable provirus through two main reactions, 3′-processing and
strand transfer.9-11 Several IN inhibitors were identified through
in vitro inhibition assays with recombinant IN,12-17 and among
them the -diketo acid (DKA) class of compounds18-20 showed
the most promising results. DKAs are comprised of three
structural components (Chart 1a): (a) a -diketo moiety, (b) an
aromatic or heteroaromatic portion, and (c) a carboxylic acid
group, which can be replaced with a variety of bioisosteric
functions. Each of these motifs lends itself to potential
structure-activity explorations.
After about 15 years of study, a DKA-based derivative, MK-
0518 (Raltegravir, Chart 1b),21-23 has been marketed for clinical
use, confirming IN as a rational retroviral drug target. Moreover,
the launch of the 4-quinolone-3-carboxylic acid GS-9137
(Elviltegravir, Chart 1b)24,25 is expected soon. Although several
synthetic and biological studies for DKA compounds have been
reported, the mechanism by which they bind IN has not been
well understood. It is believed that the DKA pharmacophoric
motif could be involved in a functional sequestration of one or
both divalent metal ions in the enzyme catalytic site to form a
ligand-M2+-IN complex.26,27 This would subsequently block the
transition state of the IN-DNA complex by competing with the
target DNA substrate, acting as “interfacial inhibitor”.7,28 DKAs
and DKA-like compounds therefore represent not only the most
important class of IN inhibitors but they also constitute a
validated prototype of metal chelating inhibitors.
We are investigating the metal complexation as a new strategy
in the IN drug design. In a recent study,1 we proposed a series
of DKA metal complexes as novel prototype of IN inhibitors.
A series of complexes were synthesized by using the DKA
ligands 1 and 2 and their methyl esters 3 and 4 (Chart 2) with
a set of divalent metal ions [Mg2+, Mn2+, Ni2+, Co2+, Cu2+,
and Zn2+]. Complexes with different stoichiometries were
isolated (5a-f, 6a-f, 7a, 8a, 9a, Chart 3), fully characterized,
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Chart 1. (a) Classical Structure and Chemotype of DKA
-Diketo-Based Inhibitors and (b) Compounds in Clinical Trials
(GS-9137) and Marketed (MK-0518)
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and then tested for IN inhibition. These complexes inhibited
HIV-1 IN at a high nanomolar to low micromolar range.
Interestingly, they exhibited a certain “metal inhibition depen-
dency” and, in particular, the Co2+ complexes, showed, for the
phenyl series (5a-f), the best biological profile. Encouraged
by these results and in order to extend our understanding of the
properties of such complexes, a series of docking studies were
performed.
Initially, the free ligands 1-4 were docked in the mon-
odeprotonated (mdp) and bis-deprotonated (bdp) forms into the
active site containing one Mg2+ ion. Then 1-4 were docked
as Mg2+ and Co2+ complexes into the active site, where the
Mg2+ ion was removed. Finally, the complexes were docked
on the protein with Mg2+ in the active site and the results from
the various docking studies were compared.
To better characterize the complexation ability of the DKA
system, we carried out a series of potentiometric measurements
to determine the equilibrium constants between 1 and 2 with
Mn2+ and Ca2+. Although Mg2+ is a more likely cofactor for
integration in cells given its abundance over Mn2+, IN prefers
Mn2+ in vitro. Ca2+ is a physiologically representative ion with
coordination chemistry similar to Mg2+. Moreover, the set of
metal complexes of 1 and 2 is increased by synthesizing their
Pd2+, Pt2+ derivatives (11 and 13), and two new Mg2+
complexes, starting from Mg(acetylacetonate)2 (10) and
Mg(NO3)2 (14). The new complexes were tested for anti-HIV-1
IN activity, and 14 demonstrated an inhibitory activity in
submicromolar range. The structure of this compound was
solved by single crystal X-ray crystallography. The possible
mode of binding and the related mechanism of action of
members of the DKA class of compounds are discussed.
Molecular Modeling
Docking of Free Ligands. The carboxylic group of 1 and 2
(pKa ∼ 4) under physiological conditions is deprotonated,1 and
it was modeled as a carboxylate for docking. On the contrary,
the 2-enolic oxygen, with the strong intramolecular H-bond with
the ketone in -position, has been considered protonated (mdp,
for 1 and 2). On the other hand, it is known that coordination
increases the acidity of the ligands, so the keto-enolate form
has also been evaluated; in this way, 1 and 2 result as
bis-deprotonated (bdp) and 3 and 4 as deprotonated (dp).
Comparison of the keto-enol (mdp) with the keto-enolate (bdp,
dp) forms showed almost identical binding orientations, with
slight deviations in the case of 1. Docking of the free ligands
showed no complexation of the active site Mg2+ ion (Figure
1). As a reference, 5CITEP19 (mdp) was docked, and a similar
orientation of the keto-enol group was found. The energies and
clustering data are listed in Table S1a of the Supporting
Information. In docking calculations, the contributions of overall
docking scores are additive, in that dimeric structures yield
higher scores than monomers. Therefore, to obtain “size-
independent” docking, a per-atom energy (i.e., the intermolecular
energy divided by the number of heavy atoms and polar
hydrogens) was calculated. This allowed a better comparison
between monomeric ligands and dimeric complexes, without
the docking score bias due to molecular sizes. Moreover, to
better dissect the metal’s contribution, the interaction energies
of the metals were subtracted from the total energies (Table
S1b of the Supporting Information).
Docking of Complexes to Protein without Mg2+ Ion in
the Active Site. Docking studies were performed with com-
plexes 5a-9a and 5d-9d. A dimeric structure was suggested
for these complexes,1 but in order to better analyze their possible
accommodations into the active site, the different ligand modes
were independently handled in the case of 5a and 6a: the
complexes were considered as monomers in the hydroxyl-
carboxylate (HC) and acetyl-acetonate (AA) forms (Chart 3).
Having in mind the good biological profile of 5d, the other Co2+
complexes 7d, 8d, and 9d were also modeled, even though they
were not synthesized. Docking of Mg2+ complexes (Figure 2A)
showed binding orientations of 9a, 5a-HC, and 5a-AA, where
the Mg2+ ion was coordinated by the catalytic diad Asp64 and
Asp116. Additionally, 5a-HC acted as H-bond acceptor with
Thr66, as did 8a with Gln148 (Figure 2). Because of their size,
complexes 6a, 7a, and 8a (Figure 2) did not fit very well in the
active site. The binding modes of the complexes and of
the corresponding free ligands differed in all cases. Docking of
Co2+ complexes (Figure 2B) showed the same orientations for
almost all the complexes (only 7d is slightly different),
compared to their magnesium counterparts. Docking energies
and clustering data are listed in Tables S2a and S2b of the
Supporting Information for Mg2+ complexes and in Tables S3a
and S3b of the Supporting Information for Co2+ complexes,
respectively.
Docking of Complexes to Protein with Mg2+ Ion in the
Active Site. Docking of 9a showed that the carboxylate group
was close to the active site magnesium ion. Its own magnesium
ion interacted with Glu92 and, overall, the ligand was relatively
exposed in the binding site (Figure 3A). 9d showed a similar
binding mode (Figure 3B). Interestingly, the 5a-HC carboxylate
group coordinated the active site Mg2+ ion while the Mg2+ ion
of 5a-AA was coordinated by the catalytic residue Asp64.
Chart 2. Ligands 1-4
Chart 3. Structural Hypothesis for the Previously Synthesized
Complexes1
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Moreover, the orientation of 5d-HC was similar to 5a-HC,
whereas the orientation of 5d-AA was different from 5a-AA
(Figure 3). The enolate group of 7a was found in close proximity
to the active site magnesium ion, and its ester functionality acted
as an H-bond acceptor with Lys159. As in all the structures
with two ligand molecules, the species could not be accom-
modated by the active site due to its large size. The replacement
of magnesium with cobalt (i.e., 7d) afforded a different
orientation, where both the enolate oxygen and the ester group
are close to the active site magnesium ion, even though not in
a good complexation geometry. Again, 6a and 6d did not show
any direct interaction with the protein besides the chelation of
the active site magnesium ion by the carboxylate group. In the
docked orientation of 8a and 8d, the pyrrole rings were exposed,
whereas the fluorophenyl rings were quite buried. No direct
interactions were observed. Additionally, the magnesium ion
of the complex is rather close to the active site ion. Docking
energies and clustering data are listed in Tables S4a and S4b
of the Supporting Information.
Discussion of Docking Results. Visual inspection of the free
ligand docking results showed similar orientations of the acids
compared to their esters. Free ligands and their corresponding
complexes in most of the cases did not have similar orientations,
as expected, due to their different interaction sites (free keto-
enol function vs coordinated metal ion). A first comparison of
the per-atom energies of the free ligands and their respective
complexes showed an energetic preference of the complex form
of 1 (i.e., 9a, 5a-AA, 5a-HC) and their cobalt counterparts.
Complexes 7a and 8a, and their cobalt counterparts 7d and 8d,
had less negative energies; this was due to their size, which
prevented a good accommodation by the protein and favorable
interactions. Similarly, 2 was supposed to form dimeric com-
plexes, but according to the per-atom energy, the free ligand
form is preferred. In the case of 9a and 6a, the question arose
whether it was possible for an active site to incorporate three
2-fold positive ions. However, a closer look on the binding
energies revealed that the energetic contributions of the com-
plexes’ metal ions were unrealistically high; therefore, the results
of the docking study without Mg2+ in the active site were not
optimal.
In contrast, the docking study with Mg2+ in the active site
yielded reasonable energetics. This was due to the occupation
by the magnesium ion of the interaction site near the catalytic
residues Asp64 and Asp116, which was responsible for unre-
alistically high energetic contributions of the complexes’ metal
ions when docked to the magnesium-free binding site (Table
S5b of the Supporting Information). Comparing the per-atom
energies of complexes with the free ligands (see Table S6b of
the Supporting Information), the complexes perform better in
case of 5a-HC and 5a-AA. As a reference, the protonated form
of the free ligands should instead be considered (see above). It
is interesting to note that, in the obtained binding modes of 5a-
AA and 7a and of their cobalt counterparts, the positioning of
the metal ions resembled the respective structural features of
ASV integrase (pdb: 1VSH), which is considered a homologous
model for the IN active site with two Mg2+. According to the
obtained docked energies, all cobalt complexes are stronger
binders than the corresponding magnesium complexes, in
agreement with the activity data.
Chemistry
Potentiometric Measurement and Calculations. Potentio-
metric studies on the solution behavior of 1 and 2 were carried
out with Ca2+ and Mn2+ (Figure 4 and Table 1). To avoid
solubility problems, all the titrations were performed in methanol/
water solution (9:1 v/v). The best fit of the experimental titration
curves was obtained by using the set of species reported in Table
1. The species found in solution with Mn2+ [H2L (diprotic
ligand), ML22-, M2L2+, M2L2, and M2L2(OH)-] are the same
as in the case of Mg2+,1 but the formation constants are greater
and show a higher stability than the former complexes. ML22-
and M2L2(OH)- were not found for Ca2+; in fact, in alkaline
solution, only Ca2L2 is present. As shown by the distribution
diagrams in Figure 4a-d, at physiological pH, the species M2L2
is the most abundant one for both ligands and metal ions. M2L2+
Figure 1. Binding modes of the top-ranked docking results for ligands 1 and 2, as monodeprotonated keto-enol (mdp, gray) and bis-deprotonated
keto-enolates (bdp, blue), and for 3 and 4 in the deprotonated form; protein is shown with magnesium ion in its active site (gray sphere). The
catalytic triad (Asp64, Asp116, Glu152) is shown in gold, and the residues interacting with the ligands are shown as green sticks. For reference,
the docked binding mode of 5CITEP (mdp) is shown.
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is formed at more acidic pH (see complex 9). The formation
constants of the monomeric species, ML, and of the dimeric
one, M2L2, cannot be refined together, probably because of their
high mathematical correlation. As already noted1 by means of
potentiometry alone, we cannot completely exclude the presence
in solution of the monomeric species, because the model with
ML instead of M2L2 is only slightly unfavorable. The reason
of our choice is due, in addition to the slightly better statistical
values, to the fact that M2L2 was also supported by spectroscopic
and molecular modeling data. In the case of Mn2+, ML22- has
been also introduced, formed by coordination of the 2-enolate
and carboxylate oxygen to the metal ion (Figure 4c,d), while
species with the monoprotonated ligand, HL-, were rejected
by the software. ML(OH)-, or its dimer M2L2(OH)2-, slightly
improve the statistical parameters of the fitting, but they are
eventually formed, if formed at all, at very alkaline pH (Figure
4a,b). Computed and experimental titration curves fit perfectly
for the experiments conducted in 1:2 and 1:4 M:L ratios for all
the examined metal:ligand couples. The slightly worse fit for
the 1:1 M:L ratio can be explained by a partial hydrolysis of
the cation, not avoided by the low quantity of ligand in solution.
In fact, in this case the titration points at intermediate pH reach
the equilibrium very slowly.
Synthesis and Characterization of the Complexes
10-14. The platinum(II) complexes of the DKA 1 (H2L1) and
2 (H2L2), as well as the palladium(II) and magnesium acety-
lacetonate complexes with 1, have been synthesized and fully
characterized (Scheme 1). 10 has been isolated by reacting 1
with Mg(acac)2, with the aim to avoid the dimeric structure of
5a and 6a by using a coligand that “blocks” two coordinating
positions around the metal. In 10, the ligand becomes completely
deprotonated, as can be inferred by the 1H NMR (no OH
resonance), and by the IR spectra (the OH absorption is no
longer visible, and the carboxylic CdO stretching mode at 1735
cm-1 in the free ligand is replaced by two bands at 1521 and
1392 cm-1, imputable to the ν(O-C-O) asymmetric and
Figure 2. Binding modes of the top-ranked docking results for Mg2+ complexes (A) and Co2+ complexes (B); protein with no magnesium ion in
its active site. For reference, the respective free ligands are shown as light-blue lines, and the position of the active site magnesium ion is marked
with a cross.
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symmetric stretching vibrations). Moreover, the 1H NMR
spectrum clearly indicates a 1:2 ligand:acac ratio, as also
confirmed by elemental analysis. Because the spectra are similar
between 10 and the previously reported magnesium complex
5a, where the ligand coordinates two metal ions through the
acetyl, hydroxyl, and carboxylic moieties, we can reasonably
assume a similar coordinating behavior for the ligand in 10. In
10, the coordinating positions around the magnesium ions are
completed by two acetylacetonate ligands (Figure 5).
Also in the palladium complex 11, the ligand is bis-
deprotonated, leading to a stoichiometry of type ML. The
complete deprotonation of the ligand is confirmed by the
spectroscopy data: in the 1H NMR spectrum, the acidic protons
are absent, while in the IR spectrum, the OH and the carboxylic
Figure 3. Binding modes of the top-ranked docking results for Mg2+ complexes (A) and Co2+ complexes (B); protein with magnesium ion in its
active site (shown as white sphere).
Table 1. Logarithms of Protonation and Mg(II) Complex Formation Constants (pqr ) [MpLqHr]/[M]p [L]q [H]r) in Methanol/Water ) 9:1 v/v, I ) 0.1
M KCl at 25 °C for the Ligands Under Study with Ca(II), Mn(II), and Mg(II)a
M ) Ca(II) M ) Mn(II) M ) Mg(II)b
p q r H2L1 H2L2 H2L1 H2L2 H2L1 H2L2
M + 2 L h ML2 1 2 0 11.58(0.29) 13.41(0.35) 8.81(0.30) 12.45(0.26)
2 M + L h M2L 2 1 0 10.42(0.06) 11.24(0.11) 10.12(0.26) 12.16(0.15) 9.43(0.17) 10.46(0.16)
2 M + 2 L h M2L2 2 2 0 18.27(0.05) 19.26(0.11) 17.85(0.16) 20.92(0.17) 14.14(0.25) 17.99(0.10)
2 M + 2 L + OH h M2L2 (OH) 2 2 -1 8.46(016) 11.62(0.17) 3.89(0.18) 7.80(0.10)
p q r H2L1b H2L2b
L + H h LH 0 1 1 9.89(0.02) 11.66(0.03)
L + 2H h LH2 0 1 2 13.70(0.04) 15.91(0.06)
a Standard deviations are given in parentheses. Charges are omitted for simplicity. b Data from ref 1.
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CdO stretching band disappear. The presence of water mol-
ecules is indicated by a broad absorption at 3450 cm-1, and it
is confirmed by elemental analysis. Unfortunately, the compound
is not stable in open air or in solution and was kept under
nitrogen. The diketo acid moiety can give rise to both a
hydroxyl-carboxylate and an acetyl-acetonate type of coordina-
tion (Chart 3). We suppose that the spectral analogies with the
other complexes lead to a dimeric structure also for 11, with
the acetyl, the hydroxyl, and the carboxylate groups of the ligand
involved in the coordination (Figure 5). A different situation is
observed for the platinum complex 12. An attempt to prepare
PtL1 has instead led to the bis-chelate Pt(HL1)2, where two
monodeprotonated ligands coordinate to the metal center. The
yield of the reaction was optimized by reacting the metal salt
and the ligand in the appropriate 1:2 stoichiometric ratio
(procedure B in the Experimental Section). In the 1H NMR
spectrum, the resonance of one acidic proton was around 14
ppm, while in the IR spectrum, the stretching band of the
carboxylic moiety was at 1625 cm-1. The shift vs the free ligand
(1735 cm-1) is therefore less than in the palladium analogue
(1557 cm-1). A similar shift has been previously observed in
the complex (1R,2R-cyclohexanediamine-N,N′)[2-hydroxy-4-
oxo-2-pentenoato]platinum(II)29and in a copper(II) complex
of H2L1.30 In both cases, it was determined by X-ray
diffraction analysis that the ligand coordinated in the acetyl
acetonate form. It is therefore plausible to assume an
acetylacetonate coordination in 12 and also in the other
platinum complex 13, whose spectroscopic characterization
was analogous. These complexes were stable both in solution
and in the solid state. Finally, compound 14 was isolated in
an attempt to obtain a complex as [Mg2L1](NO3)2 (9a) by
reacting H2L2 with Mg(NO3)2 at pH 7. It was unambiguously
characterized as [Mg(HL2)(H2L2)(OH)(H2O)] by obtaining
single crystals suitable for X-ray diffraction analysis.
Crystal Structure of the Magnesium Complex 14. In 14
complexation occurred by heptacoordination of a Mg2+ cation
to one carboxylic carbonyl of a neutral H2L2 ligand (O3), a
carboxylate oxygen (O7) of a deprotonated (HL2)-, a water
molecule (O10), two OH- anions shared between two cations
(O9), and two -OH groups belonging to a second H2L2
molecule (O2 and O4), with a final stoichiometry of
[Mg(HL2)(H2L2)(OH)(H2O)] (Figure 6 and Figure 7). The cation
coordination was quite irregular, and the Mg-O distances,
ranging between 2.22 and 2.88 Å, were rather long compared,
for example, to that of [Mg(H2O)6]2+ or RCOO-Mg (average
Mg-O in the CSD ) 2.07 Å for both cases). Together with
the O-Mg-O angles point to a 5 + 2 distorted coordination
(Table 2). The shortest distances (<2.45 Å) in the magnesium
surroundings referred to the coordination of two carboxylate
groups and a water molecule that formed a tripodal system
around the cation. Two longer contacts (between 2.55 and 2.70
Å) joined the cation to the enolic OH of H2L2 and to an OH-
anion, while the remaining two longest interactions (between
2.84 and 2.90 Å) connected the cation to a second OH- and to
the carboxylic OH adjacent to the enolic group in H2L2, forming
a weak chelate system (Figure 7). Thus, bidimensional arrays
Figure 4. Distribution diagrams for the systems under investigation
at L:M ) 2:1 (the concentration of the ligand is 4 mM): (a) L ) H2L1,
M ) Ca(II), (b) L ) H2L2, M ) Ca(II), (c) L ) H2L1, M ) Mn(II),
and (d) L ) H2L2, M ) Mn(II).
Scheme 1. Preparation of Complexes 10-14a
a Reagents and conditions: (a) methanol, Mg(acac)2 solution in methanol,
rt, 2 h; (b) methanol, Pd(CH3COO)2 solution in methanol, rt, 1 h; (c) 12
and 13: methanol, 0.1 M KOH until pH 7, K2PtCl4 in water, rt, 2-4 h; 14:
0.1 M NaOH until pH 7, Mg(NO3)2 in water, rt, 2 h.
Figure 5. Structural hypothesis for the complexes 10-13.
Figure 6. Perspective view and labeling of the asymmetric unit of
[Mg(HL2)(H2L2)(OH)(H2O)], thermal ellipsoids at the 50% level.
Relevant hydrogen bonds are dashed.
Figure 7. (5 + 2) Coordination of magnesium in 14 and symmetry
operations required to build the coordination environment.
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of magnesium cations were bridged by OH- anions along c
and by H2L2 along b, while water molecules and deprotonated
(HL2)- were coordinated to only one cation (Figure 8, left).
Double layers of ligand molecules held together by the hydroxy-
magnesium core were formed, and the fluorinated aromatic
groups were exposed on the outer surface of these layers. This
peculiar framework clearly favored the transition between
species with varying degrees of hydration and deprotonation
because the terminal carboxylate was preorganized to coordinate
to a vicinal Mg2+, and the pending water might have shifted to
bridge pairs of cations by mirroring the OH- and symmetrizing
the structure. A network of intra- and intermolecular hydrogen
bonds stabilized this arrangement. The ketoenolic moieties
formed intramolecular hydrogen bonds [O2 · · ·O1 ) 2.51(1)Å,
O2-H · · ·O1 ) 140.2(8)°; O6 · · ·O5 ) 2.55(1) Å, O6-H · · ·O5
) 144.1(8)°], the water bridges two consecutive anionic
carboxylates along b [O10 · · ·O7 ) 3.17(3) Å, O10-H1 · · ·O7
) 140(9)°; O10 · · ·O8(x, y-1, z) ) 2.88(2) Å, O10-H2 · · ·O8(x,
y-1, z) ) 133(12)°], and the hydroxyl pointed to the ketoenolic
system of a H2L2 displaced along c [O9 · · ·O2(x, y, z+1) )
Table 2. Bond Lengths (Å) and Angles (deg) of Magnesium Coordination in 14a
bond length, Å bond angles, deg bond angles, deg
Mg1-O10 2.22(2)b O10-Mg1-O3(i) 97.3(6) O4-Mg1-O9 64.9(6)
Mg1-O3(i) 2.28(1) O10-Mg1-O7(ii) 87.0(6) O4-Mg1-O2 55.4(4)
Mg1-O7(ii) 2.43(1) O3(i)-Mg1-O7(ii) 126.9(8) O4-Mg1-O3(i) 151.7(7)
Mg1-O9 2.57(3) O10-Mg1-O9 75.6(9) O4-Mg1-O7(ii) 80.3(4)
Mg1-O2 2.67(1) O3(i)-Mg1-O9 91.0(6) O4-Mg1-O9(ii) 117.9(5)
Mg1-O4 2.84(1) O7(ii)-Mg1-O9 140.3(6) O9(ii)-Mg1-O10 141(1)
Mg1-O9(ii) 2.88(3) O10-Mg1-O2 144.4(9) O9(ii)-Mg1-O9 138.7(9)
O3(i)-Mg1-O2 107.7(5) O9(ii)-Mg1-O2 73.05(6)
O7(ii)-Mg1-O2 97.2(4) O9(ii)-Mg1-O3(i) 70.0(6)
O9-Mg1-O2 78.9(6) O9(ii)-Mg1-O7(ii) 73.9(6)
O4-Mg1-O10 91.1(7)
a Symmetry transformations used to generate equivalent atoms: (i) x, y-1, z; (ii) x, y, z-1. b In parentheses are the s.u. values.
Table 3. Crystal Data and Structure Refinement for Complex 14
empirical formula C30 H26 F2 Mg N2 O10
formula weight 636.84
temperature, K 293(2)
wavelength, Å 1.54178
crystal system triclinic
space group P1
unit cell dimensions (Å, deg) a ) 21.064(4) R ) 81.887(7)
b ) 6.7136(5)  ) 92.748(9)
c ) 5.1000(4) γ ) 89.856(9)
volume, Å3 713.16(16)
Z 1
density (calculated), Mg/m3 1.483
absorption coefficient 1.221 mm-1
F(000) 330
θ range for data collection, deg 4.20-70.04
reflections collected 2702
independent reflections 2702
refinement method full-matrix least-squares on F2
data/restraints/parameters 2702/11/417
goodness-of-fit on F2 0.961
final R indices [I > 2σ(I)] R1 ) 0.0864, wR2 ) 0.2224
R indices (all data) R1 ) 0.1486, wR2 ) 0.2980
largest ∆F maximum/minimum, e ·Å-3 1.050/-0.346
Figure 8. Crystal organization of H2L2, (HL2)-, H2O, and OH- around Mg2+ in 14 (left) and crystal packing of H2L2 alone1 (right). Fluorobenzene
substituents are represented as large balls for clarity. Hydrogens omitted. Water molecules and bridging OH- anions are indicated as dark balls
around Mg2+ cations represented as light balls.
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3.31(3) Å, O9-H · · ·O2(x, y, z+1) ) 131(11)°]. Most impor-
tantly, the neutral and the anionic carboxylate facing each other
between two cations were strongly linked together [O4 · · ·O8
) 2.46(2) Å, O4-H · · ·O8 ) 170.5(9)°].
The remarkable irregularity of the solid state molecular
association in 14 was caused by the coexistence of species with
different protonation states HL2-, H2L2, OH-, and H2O, and it
was reflected by crystallization in the least symmetric space
group P1, although no chiral centers are present in the single
molecular components. The role of the magnesium cation in
the solid state organization of 14 may be grasped by comparing
its crystal structure with that of the free neutral ligand1 H2L2
(Figure 8, right). The latter pairs of H2L2 were strongly
associated with two hydrogen bonds forming the carboxylic acid
dimer pattern, whereas the introduction of the magnesium cation
destroyed the dimers by generating catemers where one
hydrogen bond between carboxylic groups was preserved and
the other was replaced by a Mg(OH)(H2O)+ bridging moiety.
Biology
Inhibition of HIV-1 IN. Complexes 10-14 were designed
to explore the chemical features required for the activity of this
class of compounds. In particular, complex 10 was prepared to
evaluate the activity of a “hybrid” complex where the organic
scaffold is constituted of a simple DKA (1) from one side and
an inactive acetylacetone from the other side. 11 followed the
trend of the complexes described in the previous series (5) but
with Pd2+ as metal ion. Complexes 12 and 13 were structurally
different for both the new metal ion (Pt2+) and their stoichi-
ometry (M:L ) 1:2). Then, we also obtained an interesting new
complex (14) with an original structural rearrangement. All of
them were tested for their ability to inhibit IN catalytic activities,
3′-processing and strand transfer, in in vitro assays employing
purified enzyme. The results, reported in comparison with those
of the previously synthesized free ligands (1 and 2) and
complexes (5a,d, 6a,d, and 9a), are summarized in Table 4.
With an IC50 value of 143 ( 15 µM, 10 was 2- and 3-fold
less active than 1 and 5a (IC50s ) 69 ( 4 and 44 ( 3 µM for
strand transfer for 1 and 5a, respectively). This indicated that
the nature of the ligands significantly influenced the inhibition
potency. Pd2+ complex 11, when tested against IN, exhibited
the same “metal inhibition dependency”, already observed in
the compounds of the series 5. Compound 11 showed an IC50
value of 20 ( 2 and 73 ( 6 µM for strand transfer and 3′-
processing, respectively (for a representative gel, see Figure 9),
and was 2-fold more potent for strand transfer than the respective
Mg2+ derivative (IC50 ) 44 ( 3 µM). This confirmed the notion
that the nature of the metal ions also influences the activity.
While the Pt2+ complex 12 resulted in a 2-fold increase in
potency (IC50 ) 35 ( 3 µM for strand transfer) compared to
the ligand 1, complex 13 showed a slight decrease in potency
(IC50 ) 2.4 ( 2 for strand transfer and 3′-processing, Figure
7), when compared with 2. However, these complexes showed
a range of potency similar to the others obtained in a 2:2
M:ligand stoichiometry, such as 5 and 6. Interestingly, the
complex 14 (IC50 ) 0.37 ( 0.23 and 6 ( 1 µM for strand
transfer and 3′-processing, respectively, Figure 7) was the most
potent compound, with 2-fold greater potency than its free ligand
2 (IC50 ) 0.54 ( 0.08 and 15 ( 2 µM for strand transfer and
3′-processing, respectively). Analysis of these results suggested
that only active ligands (e.g., DKA) were needed on the organic
scaffold to retain the intrinsic potency of this class of com-
pounds. Moreover, it was interesting to observe that not only
complexes with 2:2 metal:ligand ratio, but also 1:2 complexes
demonstrate a favorable structural combination, as revealed by
their potency.
How Do Inhibitors Bind in the Active Site?
Although the exact mechanism of action of IN inhibitors has
not been elucidated, it is believed that most IN specific inhibitors
interfere with metal ions in the IN active site. Therefore, metal
chelation at the catalytic core could be exploited in the design
of new inhibitors with better selectivity toward IN.27 Obviously,
major insights will be obtained when a crystal structure of the
enzyme complexed with its DNA substrate becomes available.
There are several unanswered questions about the exact role,
the type, and number of metal ions within the enzyme active
site. It is generally accepted that Mg2+ is a more likely cofactor
for integration in cells given its one million-fold abundance over
Mn2+, even though the activity of purified enzyme is more
robust with Mn2+ than Mg2+.
In designing selective ligands interacting with such metal ions,
structural considerations have to be invoked together with the
electronic nature of the ligand donor centers. In particular, Mg2+
prefers an octahedral coordination, but steric constraints of
polydentate ligands could prevent coordination. Mn2+ forms
mainly high-spin octahedral complexes, and it has a more
flexible coordination sphere than the smaller Mg2+. Although
Mn2+ can functionally replace Mg2+ in its catalytic and
structural role, the different electronic and geometrical features
of the two ions can explain the discrepancies observed using
different enzyme assay conditions, as well as the differences in
activity for inhibitors bearing bioisosteric pharmacophoric
fragments. Therefore, it is important to investigate the com-
Table 4. Inhibition of HIV-1 IN Catalytic Activities of Ligands and
Complexes
compd aM bM:L 3′-processingIC50 (µM)
strand transfer
IC50 (µM)
cSI
1d >333 69 ( 4 >5
2d 15 ( 2 0.54 ( 0.08 28
5ad Mg2+ 1:1 >333 44 ( 3 >8
5dd Co2+ 1:1 50 ( 9 5 ( 3 10
6ad Mg2+ 1:1 6 ( 1 0.26 ( 0.04 23
6dd Co2+ 1:1 9 ( 4 0.72 ( 0.33 12
9d Mg2+ 2:1 >333 88 ( 5 >4
10 Mg2+ 2:1 >333 143 ( 15 >2
11 Pd2+ 1:1 73 ( 6 20 ( 2 3.5
12 Pt2+ 1:2 >100 35 ( 3 >2.8
13 Pt2+ 1:2 >33 2.4 ( 2 >13
14 Mg2+ 1:2 6 ( 1 0.37 ( 0.23 16
a M ) metal ion. b M:L ) metal:ligand ratio. c SI: selectivity index.
d Data from ref 1.
Figure 9. Representative gel showing inhibition of purified IN by
selected compounds 11, 13, and 14. Lanes 1 and 12: DNA alone; lanes
2 and 14: IN and DNA with no drug; other lines: IN, DNA, and selected
drug concentrations as indicated above each lane. All inhibitor
concentrations decrease from 100 µM f 33 µM f 11 µM f 3.7 µM
f 1.4 µM.
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plexing ability of the diketo acid pharmacophore. In our study,
it is particularly interesting to note that several species [ML22-,
M2L2+, M2L2, and M2L2(OH)-] were found in solution for
Mn2+ by potentiometric titration studies (Figure 4, Table 1).
These species were the same for Mg2+,1 but with higher
stability. When the behavior of DKAs in the presence of Mg2+
was investigated, the species M2L2 are predominant at physi-
ological pH for both 1 and 2. The high affinity for the Mn2+
shown by DKAs could in part explain why many inhibitors that
were identified by high-throughput screening technology using
Mn2+ as a cofactor were inactive in the presence of Mg2+. Also,
M2L2 species were predominant at physiological pH for
Ca2+(II), with a formation constant comparable to that of the
Mn2+ (II) complex. However, the presence of a small amount
(∼10%) of ML2 was observed at physiological pH by titration
of H2L2. The experiment involving calcium ions was carried
out to both expand the evaluation of the complexation ability
and to study the affinity of DKAs toward other physiological
representative metal ions.
Another important topic to investigate is at which step of
the catalytic sequence the IN inhibitors act. This is important
for the design of novel inhibitors, as free ligands or complexes
can interfere with one or two metals either directly in a single
step or in a sequential manner. In fact, some DKAs show certain
inhibitory activity against the 3′-processing step but at a higher
concentration than strand transfer. Therefore, they can bind
before 3′-processing (for example to one Mg2+), and then they
can interfere with the other metal when it is kept in the active
site. Otherwise, they can independently and not sequentially bind
to both steps more or less strongly, depending upon the
availability of one or both metal ions. The selectivity displayed
by DKAs for the strand transfer reaction could be therefore
explained by the fact that inhibitors need both metal ions to
bind strongly and that the second metal binds only in the
presence of a DNA substrate. In fact, only one Mg2+ has been
detected in the active site in crystallographic studies,11,31 but
the presence of the viral DNA might be critical for the second
metal binding. This is a more realistic representation of the
physiological conditions. The absence of this second metal ion
in the crystal structures led to the hypothesis that the metal ion
is bound to the substrate (i.e., DNA). Considering DKAs as
competitive inhibitors of this substrate, the hypothesis of DKAs
acting as metal complexes is in good agreement with this idea.
Because we demonstrated the formation of complexes in
solution by DKAs, our studies strongly suggested the hypothesis
that these compounds can immediately form complexes in in
vitro enzymatic studies and in vivo in the presence of divalent
metal ions in the intracellular space. Following this reasoning,
the DKAs and their metal complexes may act as interfacial
inhibitors both by involving an unique mechanism and by
interfering with IN and acceptor (viral) DNA, and in this way
they may block the strand transfer reaction, as previously
suggested. Such interference with the enzyme could be due to
the following mechanisms: (a) the complex binds “as is” to IN,
it keeps its metals and occupies the binding site as a single
“static” entity, or (b) upon binding to IN, a dynamic exchange
of the metal ions occurs, and the ligand releases its complexed
metals and forms instead a complex with the metal ions in the
binding site. Molecular modeling results seem to support the
hypothesis that DKAs could act themselves as complexes, or
by forming a stable complex with the metal ions on the active
site. In fact, the complexes showed a better docking energy than
the free ligand and a more favorable accommodation in the
active site, especially when considered in the monomeric form.
In the absence of a cocrystal structure, the previously described
“two-metal binding” model inhibition mechanism could be
reasonably extended to the DKA family.
Conclusions
Both structural studies on HIV-1 IN inhibitors and the biology
of metal cofactors have confirmed the important role of metal
ions in the inhibition process and that the metal ion binding
function is a critically important factor in the development of
IN inhibitors. In this study, we extended the investigation of
the complexing ability of DKAs in solution by considering other
representative divalent metal ions, and we performed a molecular
recognition study of the binding mode of free ligands and
complexes by means of a molecular modeling docking approach.
Furthermore, we obtained new insights from the biological
investigation of a new set of synthesized complexes. Although
we do not have a clear explanation concerning the possible
interaction of these inhibitors at the molecular level, analysis
of all results seems to support the hypothesis that members of
the DKA class could act themselves as complexes or at least
form a stable complex with metal ions on the IN active site.
Of course, further experiments are needed to confirm this
assumption. For example, from the molecular dynamics studies
with a second metal ion in the active site, it seems that the third
catalytic residue, Glu152, which in the crystal structure points
away from the active site, tilts toward the second metal ion and
the active site.32 This might also happen upon binding of an
inhibitor-metal complex, and it therefore plays an important
role in terms of protein-ligand interaction energies. Besides,
the biological evaluation of a greater number of complexes, with
DKA or DKA-based compounds as ligands, would be useful
for a careful SAR rationalization. Work is in progress in this
direction to obtain more information for clarifying the complex’s
behavior. Finally, our studies suggest that the metal chelation
strategy can not only help in designing second generation IN
inhibitors and the understanding of IN mechanism, but it can
also be extended to other enzymes of therapeutic importance.
Experimental Section
Chemistry. All reagents of commercial quality were used without
further purification. Proton NMR spectra were recorded at 27 °C
on a Bruker 300 FT spectrophotometer by using TMS as internal
standard, while IR spectra were obtained with a Nicolet 5PCFT-
IR spectrophotometer in the 4000-400 cm-1 range, using KBr
disks or, where indicated, the reflectance mode on the powder.
Elemental analyses were performed by using a Carlo Erba model
EA 1108 apparatus.
The ligands H2L1 (1) and H2L2 (2) were prepared as previously
described.1
Preparation of the Complexes 10-14. Mg2(L1)(acac)2 ·
2H2O (10). H2L1 (0.1 g, 0.5 mmol) was dissolved in 15 mL of
methanol and added dropwise to a methanolic solution of Mg(acac)2
(1 mmol; acac ) acetylacetonate). The solution was light yellow
and the final pH neutral. The reaction mixture was stirred at room
temperature for 2 h and concentrated under vacuum to obtain a
white powder; yield: 75%; mp > 280 °C. IR (cm-1): νCdO ) 1597,
1521, 1392. 1H NMR (DMSO-d6): δ 7.95 (d, br, 2H, Harom), 7.50
(m, 3H, Harom), 7.04 (s, br, 1H, CHenolic), 5.08 (s, br, 2H, CHacac),
1.75 (s, 12H, CH3). Anal. (C20H20O8Mg2 ·2H2O) C, H.
PdL1 ·H2O (11). H2L1 (0.1 g) was dissolved in dry methanol
under nitrogen and added to an equimolar solution of Pd(CH3COO)2
in methanol (15 mL). After 1 h at room temperature, a brown
precipitate formed, which was filtered off, washed with methanol,
and dried under vacuum. The product is unstable in solution and
in open air and so it was kept under nitrogen; yield: 82%. IR
(cm-1): νOH ) 3450; νCdO ) 1557, 1348. 1H NMR (DMSO-d6): δ
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7.88 (d, 2H, Harom), 7.62 (t, 1H, Harom), 7.50 (t, 2H, Harom), 4.60 (s,
1H, CHenolic). Anal. (C10H6O4Pd ·H2O) C, H.
Pt(HL1)2 (12). Procedure A: H2L1 (0.5 mmol) was dissolved in
10 mL of methanol and the pH adjusted to 7 by using KOH (1M).
The solution of the ligand was added dropwise to an aqueous
solution of K2PtCl4 (0.5 mmol). The reaction mixture was stirred
at room temperature for 2 h and monitored by TLC (CHCl3:CH3OH
7:3). The solution was deep orange. The solvent was eliminated
under vacuum and the residue retrieved with methanol and
dichloromethane. A solid was separated (salt in excess). The yellow
filtrate was concentrated and passed over celite to eliminate residual
KCl; finally a yellow powder was isolated, washed with diethyl
ether, and dried under vacuum; mp ) 190-192 °C (dec). IR
(cm-1): νCdO ) 1625, 1383. 1H NMR (DMSO-d6): δ 14.51 (s, br,
1H, OH), 8.03 (d, 2H, Harom), 7.67 (t, 1H, Harom), 7.56 (t, 2H,
CHarom), 6.99 (s, 1H, br, Henolic). Anal. (C20H14O8Pt) C, H. Procedure
B: H2L1 (0.5 mmol) was dissolved in 10 mL of methanol and the
pH adjusted to 7 by using KOH (1M). The solution of the ligand
was added dropwise to an aqueous solution of K2PtCl4 (0.25 mmol).
The reaction mixture was stirred at room temperature for 4 h. The
solution was bright yellow. The solvent was removed under vacuum,
and a yellow powder was isolated, washed with diethyl ether, and
dried under vacuum.
Pt(HL2)2 (13). The same as Pt(HL1)2, procedure B, by using
H2L2; yellow powder; mp > 250 °C. IR (cm-1): νCdO ) 1633,
1394. 1H NMR (DMSO-d6): δ 13.84 (s, br, 1H, OH), 7.18 (d, 2H,
Harom), 7.01 (d, 2H, Harom), 6.73 (s, 1H, CHenolic), 6.38 (s, 1H, Himid),
6.19 (s, 1H, Himid), 5.90 (s, 1H, Himid), 5.64 (s, 2H, CH2). Anal.
(C30H22F2N2O8Pt) C, H, N.
Mg(HL2)(H2L2)(OH)(H2O) ·2H2O (14). H2L2 (0.5 mmol) was
dissolved in 15 mL of methanol and water (1:1) and the pH adjusted
to 7 by using a 0.1 M aqueous solution of NaOH. The ligand was
then added dropwise to an aqueous solution of Mg(NO3)2 (1 mmol).
The reaction mixture was stirred at room temperature for 2 h and
then the solvent was removed under vacuum. The residue was
retrieved with methanol, filtered, and concentrated until a highly
hygroscopic white powder was isolated. IR (reflectance mode,
cm-1): νOH ) 3401, νCdO ) 1584. 1H NMR (DMSO-d6):
δ7.32-6.90 (m, 12H, Harom+CHimid), 6.72 (s, br, 2H, CHimid), 6.16
(s, br, 2H, CHimid), 5.95 (s, br, 1H, OH), 5.66 (s, br, 4H, CH2),
5.36 (s, br, 1H, OH). Anal. (C30H26F2Mg N2O10 ·2H2O) C, H, N.
Potentiometric Measurements. Materials. The metal ions stock
solutions were prepared from CaCl2 ·6H2O (Carlo Erba) and
MnCl2 ·4H2O (Janssen), and their concentrations were determined
by using EDTA as titrant. The sodium salt of Methylthymol Blue
for Ca2+ and Eriochrome Black T in presence of triethanolamine
and hydroxylamine chloride for Mn2+ were used as indicators.
Measurements. Equilibrium constants for protonation and
complexation reactions were determined by potentiometric mea-
surements, in methanol/water ) 9:1 v/v solution at ionic strength
of 0.1 M KCl and 25 ( 0.1 °C in the pH range 2.5-11 under N2.
Temperature was controlled to (0.1 °C by using a thermostatic
circulating water bath (ISCO GTR 2000 IIx). Appropriate aliquots
of ligand solution, prepared by weight, were titrated with standard
KOH (methanol/water ) 9:1 v/v, I ) 0.1 M KCl) with and without
metal ions. Constant-speed magnetic stirring was applied through-
out. Freshly boiled methanol and double distilled water, kept under
N2, were used throughout. The experimental procedure for deter-
mination of accurate equilibrium constants in this mixed solvent
has been described in detail elsewhere.33 The protonation constants
of the ligands were obtained by titrating 20-50 mL samples of
each ligand (5 × 10-3-7 × 10-3 M). For the complex formation
constants, the titrations were performed with different ligand/metal
ratios (1 up to 4). At least two measurements (about 60 experimental
points in each) were performed for each system. Potentiometric
titrations were carried out by a fully automated apparatus equipped
with a CRISON GLP 21-22 digital voltmeter (resolution 0.1 mV)
and a 5 mL Metrohm Dosimat 655 autoburette, both controlled by
in-house software, written in BASIC, working on an IBM computer.
The electrodic chain (Crison 5250 glass electrode and KCl 0.1 M
in methanol/water ) 9:1 v/v calomel electrode, Radiometer 401)
was calibrated in terms of [H+] by means of a strong acid-strong
base titration, by the Gran’s method,34 allowing the determination
of the standard potential, Eo (373.7 ( 0.1 mV) and of the ionic
product of water, Kw (pKw ) 14.38 ( 0.01) in the experimental
conditions used. The software HYPERQUAD35 was used to
evaluate the protonation and complexation constants from EMF
data.
X-Ray Crystallography. Single crystal X-ray diffraction analysis
of 14 was carried out at room temperature with a computer-
controlled Siemens AED diffractometer using Cu KR (λ ) 1.54178
Å). No crystal decay was observed. The intensity data were
processed with a peak-profile analysis procedure and corrected for
Lorentz and polarization effects. The phase problem was solved
by direct methods, using SIR 2004.36 Full-matrix least-squares
refinements were carried out with SHELXS 97,37 implemented in
the WinGX package.38 Anisotropic thermal displacement param-
eters were refined for all non-H atoms. H atoms were introduced
in calculated positions, riding on their carrier atoms. The positions
of hydrogen atoms of H2O and OH- were optimized and restrained
to make best hydrogen bond contacts to neighboring acceptors. The
Cambridge Crystallographic Database software39 and PARST9740
were used for analyzing and drawing the molecular structure. Data
concerning structure solution and refinement are in Table 3.
Biology. Biological Materials, Chemicals, and Enzymes. All
compounds were dissolved in DMSO, and the stock solutions were
stored at -20 °C. The γ[32P]-ATP was purchased from Perki-
nElmer. The expression system for wild-type IN was a generous
gift of Dr. Robert Craigie, Laboratory of Molecular Biology,
NIDDK, NIH, Bethesda, MD.
Preparation of Oligonucleotide Substrates. The oligonucle-
otides 21top, 5′-GTGTGGAAAATCTCTAGCAGT-3′ and 21bot,
5′-ACTGCTAGAGATTTTCCACAC-3′ were purchased from Nor-
ris Cancer Center Core Facility (University of Southern California)
and purified by UV shadowing on polyacrylamide gel. To analyze
the extent of 3′-processing and strand transfer using 5′-end labeled
substrates, 21top was 5′-end labeled using T4 polynucleotide kinase
(Epicenter, Madison, WI) and γ [32P]-ATP (Amersham Biosciences
or ICN). The kinase was heat-inactivated and 21bot was added in
1.5 molar excess. The mixture was heated at 95 °C, allowed to cool
slowly to room temperature and run through a spin 25 mini-column
(USA Scientific) to separate annealed double-stranded oligonucle-
otide from unincorporated material.
Integrase Assays. To determine the extent of 3′-processing and
strand transfer, wild-type IN was preincubated at a final concentra-
tion of 200 nM with the inhibitor in reaction buffer (50 mM NaCl,
1 mM HEPES, pH 7.5, 50 µM EDTA, 50 µM dithiothreitol, 10%
glycerol (w/v), 7.5 mM MnCl2, 0.1 mg/mL bovine serum albumin,
10 mM 2-mercaptoethanol, 10% DMSO, and 25 mM MOPS, pH
7.2) at 30 °C for 30 min. Then, 20 nM of the 5′-end 32P-labeled
linear oligonucleotide substrate was added, and incubation was
continued for an additional 1 h. Reactions were quenched by the
addition of an equal volume (16 µL) of loading dye (98% deionized
formamide, 10 mM EDTA, 0.025% xylene cyanol and 0.025%
bromophenol blue). An aliquot (5 µL) was electrophoresed on a
denaturing 20% polyacrylamide gel (0.09 M tris-borate pH 8.3, 2
mM EDTA, 20% acrylamide, 8 M urea).
Gels were dried, exposed in a PhosphorImager cassette, analyzed
using a Typhoon 8610 variable mode imager (Amersham Bio-
sciences), and quantitated using ImageQuant 5.2. Percent inhibition
(% I) was calculated using the following equation:
%I) 100 × [1- (D-C) ⁄ (N-C)]
where C, N, and D are the fractions of 21-mer substrate converted
to 19-mer (3′-processing product) or strand transfer products for
DNA alone, DNA plus IN, and IN plus drug, respectively. The
IC50 values were determined by plotting the logarithm of drug
concentration versus percent inhibition to obtain concentration that
produced 50% inhibition.
Molecular Modeling. AutoDock 3.041 was used as the docking
tool, 2D structures of the complexes were derived from ref 1. The
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free ligand structures were generated by converting smiles to mol2
format using CORINA.42 Gasteiger charges and hydrogens were
added using Sybyl 7.1.43 For the respective complexes, metal ions
were added manually in Sybyl 7.1 and placed in a 2 Å distance to
the chelating oxygens, and charges of +2.0 were assigned. The
bonds belonging to the conjugated system as well as the internal
keto-enol hydrogen bond were not allowed to rotate during docking.
The modified 1QS4 structure was used as pdb input.44 Standard
parameters were used for docking, with 50 runs for each experiment
and a maximum of 3000000 energy evaluations per run. The grid
box was centered at the active site Mg2+ ion coordinates, with the
size of 22.5 Å in each direction. The clustering tolerance was set
to 1.0 Å rms. Because parameters for the cobalt ion in complexes
had not been implemented in AutoDock, the following estimates
were used: for the nonbonded 12-6 interaction grid map, param-
eters were set to r(Co) ) 1.30 Å and ε(Co) ) 0.150 kcal/mol.45
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